eli lilly glp-1 agonist FDA approves Foundayo, an oral alternative to Wegovy and Ozempic Orforglipron: Eli Lilly's New Oral

doi: 10.1007/5584_2020_496 [DOI] [PubMed] [Google Scholar] 143.Hurren KM, Pinelli NR

I would be cautious with that approach

Sanchez-Rangel E, Inzucchi SE

Additionally, a 2024 study in Diabetes Epidemiology and Management found that oral semaglutide reduced hemoglobin A1C by an average of 3.1%

On one hand, they offer a real chance to improve employee health, reduce long-term medical costs, and boost workplace productivity

New medications under FDA review, such as dual and triple agonists, are showing 20-30% weight loss in trials, monthly dosing options, and more flexible oral formulations are all in late-stage development